Gammagard Liquid10% (Baxter) in second Alzheimers Disease Phase III trial

Baxter International Inc. will initiate a second Phase III trial to evaluate the use of its Gammagard Liquid 10% [Immune Globulin Infusion (Human)] (marketed as Kiovig outside the United States and Canada), for the treatment of mild to moderate Alzheimer's Disease. The company plans to initiate the new trial in the first quarter of 2012, having satisfactorily completed a futility analysis in its first Phase III trial known as the Gammaglobulin Alzheimer's Partnership (GAP) trial. After reviewing the futility analysis, the Data Safety Monitoring Board stated the ongoing GAP study could continue without modification. Baxter looks forward to seeing the final data in 2013 regarding the trial's endpoints, specifically whether Gammagard Liquid 10% will be a viable option for the treatment of this disease.